Oncovir

Activating Innate and Adaptive Immunity

Washington, United States · Founded 2016 · $1.5M raised

Employees
1–10
Founded
2016
Business Model
B2B
Total Funding
$1.5M
Last Round
$1.5M GrantSep 2016
Rounds
1

About

Oncovir is a clinical-phase biotechnology business developing Hiltonol, also known as Poly ICLC, for oncology and infectious-disease applications. The product is positioned as an immunotherapy drug and vaccine adjuvant that mimics viral signals and broadly activates innate and adaptive immunity. Oncovir manufactures clinical material for approved regulatory settings and preclinical material for scientific exploration, and works with commercial companies and academic institutions through indication, collaboration, and territory-based partnerships.

Summary

Oncovir is a Biotech company based in Washington, United States, founded in 2016. It has raised $1.5M in total across 1 round, most recently a $1.5M Grant round in Sep 2016.

Tech & App Stack

8 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

GrantSBIR Phase II (NIH)Sep 2016
$1.5M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Oncovir on Indexed.vc
<a href="https://indexed.vc/companies/oncovir"><img src="https://indexed.vc/api/badge/company/oncovir" alt="Oncovir on Indexed.vc" width="260" height="76" /></a>